0001209191-24-000765.txt : 20240104
0001209191-24-000765.hdr.sgml : 20240104
20240104161518
ACCESSION NUMBER: 0001209191-24-000765
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dunn Edmund
CENTRAL INDEX KEY: 0001989401
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40522
FILM NUMBER: 24512064
MAIL ADDRESS:
STREET 1: MONTE ROSA THERAPEUTICS, INC.
STREET 2: 321 HARRISON AVENUE, SUITE 900
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc.
CENTRAL INDEX KEY: 0001826457
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 HARRISON AVENUE
STREET 2: SUITE 900
CITY: BOSTON
STATE: MA
ZIP: 02118
BUSINESS PHONE: 617-949-2643
MAIL ADDRESS:
STREET 1: 321 HARRISON AVENUE
STREET 2: SUITE 900
CITY: BOSTON
STATE: MA
ZIP: 02118
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-02
0
0001826457
Monte Rosa Therapeutics, Inc.
GLUE
0001989401
Dunn Edmund
MONTE ROSA THERAPEUTICS, INC.
321 HARRISON AVENUE, SUITE 900
BOSTON
MA
02118
0
1
0
0
Principal Accounting Officer
0
Stock Option (Right to Buy)
5.71
2024-01-02
4
A
0
25000
0.00
A
2034-01-01
Common Stock
25000
25000
D
Stock Option (Right to Buy)
5.71
2024-01-02
4
A
0
35900
0.00
A
2034-01-01
Common Stock
35900
35900
D
25% of this option shall vest and become exercisable on October 2, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
/s/ Markus Warmuth, Attorney-in-Fact
2024-01-04